Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease

BACKGROUND: TreXTAM(® )is a combination of the key regulatory cytokine transforming growth factor beta (TGFβ) and all trans retinoic acid (ATRA) microencapsulated for oral delivery to immune structures of the gut. It is in development as a novel treatment for inflammatory bowel disease (IBD). AIM: T...

Full description

Saved in:
Bibliographic Details
Published in:World J Gastrointest Pharmacol Ther
Main Authors: Hammer, Laura, Furtado, Stacia, Mathiowitz, Edith, Auci, Dominick L
Format: Artigo
Language:Inglês
Published: Baishideng Publishing Group Inc 2020
Subjects:
Basic Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7667406/
https://ncbi.nlm.nih.gov/pubmed/33251033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4292/wjgpt.v11.i5.79
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items